公开(公告)号：US20240123004A1

公开(公告)日：2024-04-18

申请号：US18264737

申请日：2022-02-08

Applicant: UNIVERSITY OF HOUSTON SYSTEM

Inventor： Shaun ZHANG ,  Xinping FU

IPC: A61K35/763 ,  A61P35/00 ,  C07K14/705 ,  C12N7/00

CPC classification number: A61K35/763 ,  A61P35/00 ,  C07K14/70503 ,  C12N7/00 ,  C12N2710/16632 ,  C12N2710/16651

Abstract: This invention relates to oncolytic viruses which are more resistant to neutralization and phagocytosis by immune systems, and methods for their preparation and treatment of disorders and diseases (such as cancer) with them. Described herein is an oncolytic Herpes Simplex Virus Type 1 (HSV-1) or Herpes Simplex Virus Type 2 (HSV-2) treated in immune sera that contain a high level of anti-HSV antibodies. In one preferred embodiment, the oncolytic virus includes an extracellular CD47 domain inserted into the N-terminus of a glycoprotein in order to inhibit phagocyte activity. The oncolytic virus is suitable for systemic administration for the treatment of cancer.

公开(公告)号：US20230295661A1

公开(公告)日：2023-09-21

申请号：US18184568

申请日：2023-03-15

Applicant: University of Houston System

Inventor： Shaun ZHANG ,  Xinping FU

IPC: C12N15/86 ,  C07K14/705 ,  A61K35/763 ,  A61K9/00 ,  A61P25/00

CPC classification number: C12N15/86 ,  C07K14/70596 ,  A61K35/763 ,  A61K9/0019 ,  A61P25/00

Abstract: This invention relates to herpes simplex virus (HSV) based vectors for delivering transgenes (e.g., a therapeutic gene) which are more resistant to neutralization, phagocytosis, and NK cells by immune systems, and methods for their preparation and treatment of disorders and diseases (such as those related to gene expression) with them. In one embodiment, the HSV vectors are prepared by treatment in immune sera that contain a high level of anti-HSV antibodies. The HSV vectors may include an extracellular CD47 domain inserted into the N-terminus of a glycoprotein in order to inhibit phagocyte activity, and the absence of gE for evading NK cells.